AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17323595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (phosphodiesterase type 5 inhibitor)
Number of subjects: 0
Study 17323595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 15206088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment-based product
Number of subjects: 60
Study 15206088 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol spray
Number of subjects: 60
Study 15206088 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 11148806 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sequential HRT
Number of subjects: 82
Study 11148806 — intervention group
Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 82
Study 9102063 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP-SR (76 mg b.i.d.)
Number of subjects: 17
Study 9102063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8406965 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐phase gutta‐percha delivered with a plastic core‐carrier, Thermafil
Number of subjects: 51
Study 8406965 — intervention group
Group type: COMPARATOR
Intervention: standard beta‐phase gutta‐percha with lateral condensation
Number of subjects: 51
Study 3517388 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BC)
Number of subjects: 140
Study 3517388 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (CC)
Number of subjects: 140
Study 30201101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (10-year duration)
Number of subjects: 3802
Study 30201101 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3802
Study 26650434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (2.2 g protein/kg/day)
Number of subjects: 100
Study 26650434 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein diet (1.1 g protein/kg/day)
Number of subjects: 100
Study 25899445 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg weekly dose of sirolimus (SIR)
Number of subjects: 34
Study 25899445 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 34
Study 23537892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous B-type natriuretic peptide (BNP)
Number of subjects: 16
Study 23537892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 16
Study 21911349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-paced television cartoon
Number of subjects: 60
Study 21911349 — intervention group
Group type: COMPARATOR
Intervention: Educational cartoon
Number of subjects: 60
Study 21911349 — intervention group
Group type: COMPARATOR
Intervention: Drawing for 9 minutes
Number of subjects: 60
Study 18926433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline 10 mg
Number of subjects: 301
Study 18926433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline 20 mg
Number of subjects: 301
Study 18926433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg
Number of subjects: 301
Study 18926433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 16283422 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 1041
Study 16283422 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 1041
Study 16283422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study 12690275 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (3 standard injections at 30-day intervals)
Number of subjects: 74
Study 12690275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication or vaccination)
Number of subjects: 74
Study 12690275 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine
Number of subjects: 74
Study 12690275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 12579420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 5 ml/kg
Number of subjects: 20
Study 12579420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 ml/kg
Number of subjects: 20
Study 12579420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 15 ml/kg
Number of subjects: 20
Study 12579420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 5 ml/kg after volume resuscitation
Number of subjects: 20
Study 12579420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 ml/kg after volume resuscitation
Number of subjects: 20
Study 12579420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 15 ml/kg after volume resuscitation
Number of subjects: 20
Study 10573247 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual snoring
Number of subjects: 1186
Study 8735575 — intervention group
Group type: EXPERIMENTAL
Intervention: Social feedback
Number of subjects: 60
Study 8735575 — intervention group
Group type: COMPARATOR
Intervention: Computer feedback
Number of subjects: 60
Study 8735575 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 60
Study 1820897 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA capsule formulation
Number of subjects: 0
Study 1820897 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine treatment
Number of subjects: 0
Study 1820897 — intervention group
Group type: COMPARATOR
Intervention: Single unit tablet of 5‐ASA
Number of subjects: 0
Study 6349765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG) maintenance therapy
Number of subjects: 44
Study 6349765 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (orally administered)
Number of subjects: 44
Study 26951205 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolic-rich olive leaf extract (OLE) 136 mg oleuropein; 6 mg hydroxytyrosol
Number of subjects: 60
Study 26774673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) supplementation (2 × 500 mg/day for four months)
Number of subjects: 0
Study 26774673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24838678 — intervention group
Group type: EXPERIMENTAL
Intervention: B2 regimen (two meals a day: breakfast and lunch)
Number of subjects: 54
Study 24838678 — intervention group
Group type: COMPARATOR
Intervention: A6 regimen (six smaller meals)
Number of subjects: 54
Study 22784030 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (walking and cycling, 30-45 min, 3-5 days·week⁻¹)
Number of subjects: 22
Study 22784030 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 20812996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI)
Number of subjects: 16
Study 17653942 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity rehabilitation (4-hour/day)
Number of subjects: 68
Study 17653942 — intervention group
Group type: COMPARATOR
Intervention: Control rehabilitation (2-hour/day)
Number of subjects: 68
Study 15786549 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Number of subjects: 115
Study 15786549 — intervention group
Group type: COMPARATOR
Intervention: 7-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Number of subjects: 115
Study 15786549 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based triple therapy
Number of subjects: 115
Study 15786549 — intervention group
Group type: COMPARATOR
Intervention: 7-day rabeprazole-based triple therapy
Number of subjects: 115
Study 11932292 — intervention group
Group type: EXPERIMENTAL
Intervention: fenproporex 25 mg/d
Number of subjects: 31
Study 11932292 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine 10 mg/d
Number of subjects: 31
Study 11932292 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg tid
Number of subjects: 31
Study 9428449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate bath of 40 mEq/L (experimental group)
Number of subjects: 36
Study 9428449 — intervention group
Group type: COMPARATOR
Intervention: Standard bicarbonate bath of 35 mEq/L (control group)
Number of subjects: 36
Study 8085374 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf(66)n, a chimeric molecule derived from Plasmodium falciparum proteins, details on dosage and duration not available
Number of subjects: 0
Study 2547325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-N2O/O2 (60:40)
Number of subjects: 60
Study 2547325 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (adults, 0.9%; children, 1.2%)
Number of subjects: 60
Study 2547325 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (adults, 0.6%; children, 0.7%)
Number of subjects: 60
Study 1008247 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 60
Study 1008247 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of infusion regimen (substituting glucose solution with distilled water and Ringer lactate with normal saline and 5 mval/l KCI)
Number of subjects: 60
Study 1008247 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused sodium and water
Number of subjects: 60
Study 30484833 — intervention group
Group type: EXPERIMENTAL
Intervention: Any oral anticoagulant
Number of subjects: 12417
Study 30484833 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants (DOACs)
Number of subjects: 12417
Study 30484833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 12417
Study 30484833 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 12417
Study 30484833 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 12417
Study 26817808 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and general discussions (Group B)
Number of subjects: 274
Study 26817808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy and general discussions (Group C)
Number of subjects: 274
Study 26817808 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone (Group A)
Number of subjects: 274
Study 26116494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study 26116494 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 26116494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24064776 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotor pesticide safety training program
Number of subjects: 0
Study 24064776 — intervention group
Group type: COMPARATOR
Intervention: Standard video‐based training
Number of subjects: 0
Study 20194455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbiologic DMARD treatment after 12 weeks
Number of subjects: 0
Study 20194455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low response to treatment at 12 weeks
Number of subjects: 0
Study 20194455 — intervention group
Group type: EXPERIMENTAL
Intervention: High clinical disease activity thereafter
Number of subjects: 0
Study 18955912 — intervention group
Group type: EXPERIMENTAL
Intervention: No physical protection
Number of subjects: 26
Study 18955912 — intervention group
Group type: EXPERIMENTAL
Intervention: C-collar
Number of subjects: 26
Study 18955912 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual in-line immobilization
Number of subjects: 26
Study 18955912 — intervention group
Group type: COMPARATOR
Intervention: All techniques (No physical protection, C-collar, Manual in-line immobilization)
Number of subjects: 26
Study 16869005 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational health interventions (OHI)
Number of subjects: 148
Study 16869005 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial
Number of subjects: 148
Study 16869005 — intervention group
Group type: COMPARATOR
Intervention: Controlled trial
Number of subjects: 148
Study 16869005 — intervention group
Group type: COMPARATOR
Intervention: Interrupted time-series
Number of subjects: 148
Study 16869005 — intervention group
Group type: COMPARATOR
Intervention: Different design
Number of subjects: 148
Study 14668283 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA; 400 microg)
Number of subjects: 4926
Study 14668283 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid + Iron (60 mg)
Number of subjects: 4926
Study 14668283 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid + Iron + Zinc (30 mg)
Number of subjects: 4926
Study 14668283 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (MNs)
Number of subjects: 4926
Study 14668283 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin A only)
Number of subjects: 4926
Study 11289091 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine and ketorolac
Number of subjects: 22
Study 11289091 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 22
Study 9428033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus Mini 22 Cochlear Implant System with SPEAK coding strategy
Number of subjects: 168
Study 9428033 — intervention group
Group type: COMPARATOR
Intervention: Clarion Cochlear Implant System with CIS coding strategy (and one with CA coding strategy)
Number of subjects: 168
Study 9428033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus Mini 22 Cochlear Implant System
Number of subjects: 168
Study 9428033 — intervention group
Group type: COMPARATOR
Intervention: Clarion Cochlear Implant System
Number of subjects: 168
Study 10133873 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition
Number of subjects: 51
Study 10133873 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 51
Study 3329207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 41
Study 2516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (53% carbohydrate)
Number of subjects: 0
Study 2516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-based diet (55% fat)
Number of subjects: 0
Study 2516090 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose administration (D5W)
Number of subjects: 0
Study 2516090 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of feeding (general)
Number of subjects: 0
Study 31793386 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about andropause health
Number of subjects: 80
Study 31793386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 30701617 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate‐intensity exercise + prior carbohydrate intake (10 g per person)
Number of subjects: 8
Study 30701617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high‐intensity exercise + prior carbohydrate intake
Number of subjects: 8
Study 30701617 — intervention group
Group type: COMPARATOR
Intervention: Continuous moderate‐intensity exercise
Number of subjects: 8
Study 28291781 — intervention group
Group type: EXPERIMENTAL
Intervention: GP's personal letter with an evidence-based leaflet about overcoming barriers to accessing help for memory problems.
Number of subjects: 6378
Study 28291781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 6378
Study 26124907 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg OD for 12 weeks)
Number of subjects: 45
Study 26124907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg OD for 12 weeks)
Number of subjects: 45
Study 26124907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg OD) + Atorvastatin (10 mg OD for 12 weeks)
Number of subjects: 45
Study 26124907 — intervention group
Group type: COMPARATOR
Intervention: Control (No treatment)
Number of subjects: 45
Study 23872701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive interoceptive exposure (IE)
Number of subjects: 120
Study 23872701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interoceptive exposure (IE) as prescribed in Panic Control Treatment
Number of subjects: 120
Study 23872701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interoceptive exposure (IE) without controlled breathing
Number of subjects: 120
Study 23872701 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing control
Number of subjects: 120
Study 21291436 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 150
Study 21291436 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 150
Study 19843741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contrast media
Number of subjects: 131
Study 19843741 — intervention group
Group type: EXPERIMENTAL
Intervention: IV contrast media
Number of subjects: 131
Study 19843741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and IV contrast media
Number of subjects: 131
Study 19843741 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated low radiation dose
Number of subjects: 131
Study 19843741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contrast)
Number of subjects: 131
Study 17402790 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 17402790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 0
Study 17402790 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific antibodies
Number of subjects: 0
Study 17402790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antibodies
Number of subjects: 0
Study 17402790 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF or VEGF receptor blockers
Number of subjects: 0
Study 17402790 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat shock protein 90 inhibitors
Number of subjects: 0
Study 17402790 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-targeted kinase inhibitors (sunitinib, sortenib)
Number of subjects: 0
Study 12888156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline treatment
Number of subjects: 0
Study 12888156 — intervention group
Group type: COMPARATOR
Intervention: No anthracycline treatment
Number of subjects: 0
Study 12888156 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 10579147 — intervention group
Group type: EXPERIMENTAL
Intervention: Celgene formulations (two formulations)
Number of subjects: 17
Study 10579147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tortuga formulation
Number of subjects: 17
Study 10579147 — intervention group
Group type: EXPERIMENTAL
Intervention: All three formulations
Number of subjects: 17
Study 8738686 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 50
Study 8738686 — intervention group
Group type: COMPARATOR
Intervention: rocuronium 0.6 mg kg‐1
Number of subjects: 50
Study 1680649 — intervention group
Group type: EXPERIMENTAL
Intervention: 19.2 mg oral dose of [14C]PV
Number of subjects: 0
Study 1680649 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.9 mg iv dose of [14C]PV
Number of subjects: 0
Study 1680649 — intervention group
Group type: COMPARATOR
Intervention: 40 mg nonradiolabeled oral dose of PV
Number of subjects: 0
Study 6802413 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (average weekly doses of more than 4 g)
Number of subjects: 0
Study 6802413 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who received less or no desferrioxamine)
Number of subjects: 0
Study 31843024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 84
Study 31843024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg/day
Number of subjects: 84
Study 31843024 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg/day
Number of subjects: 84
Study 31843024 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 20 mg/day
Number of subjects: 84
Study 31843024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone or Hydrochlorothiazide with Amiloride
Number of subjects: 84
Study 28276079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tackling Teenage Training (TTT) program
Number of subjects: 189
Study 28276079 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 189
Study 25367904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 hours
Number of subjects: 526
Study 23592567 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZoMaxx)
Number of subjects: 199
Study 23592567 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (Taxus)
Number of subjects: 199
Study 21707862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet therapy intervention for 6 weeks
Number of subjects: 21
Study 21707862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pet therapy)
Number of subjects: 21
Study 19779146 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 150
Study 19779146 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin and noradrenaline selective reuptake inhibitor (SNRI)
Number of subjects: 150
Study 19779146 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 150
Study 17005087 — intervention group
Group type: EXPERIMENTAL
Intervention: Simotang oral liquid
Number of subjects: 90
Study 17005087 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin enema
Number of subjects: 90
Study 17005087 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 90
Study 15612839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 367
Study 15612839 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 367
Study 10731485 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine infusion
Number of subjects: 8
Study 10731485 — intervention group
Group type: COMPARATOR
Intervention: Conventional treadmill exercise
Number of subjects: 8
Study 8957970 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy
Number of subjects: 26